<DOC>
	<DOCNO>NCT00847834</DOCNO>
	<brief_summary>To analyse control rate irbesartan/hydrochlorothiazide ( HCTZ ) ( COAPROVEL ) treatment patient mild moderate primary hypertension .</brief_summary>
	<brief_title>Irbesartan-Hydrochlorothiazide Phase IV Study : Treatment Hypertension Chinese Population</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion criterion : Systolic blood pressure &lt; 180 mmHg 90 mmHg ≤ Diastolic blood pressure &lt; 110 mmHg Exclusion criterion : Pregnancy lactation . Women child bear potential ( postmenopausal ) use reliable contraceptive method Known suspect secondary hypertension ( e.g. , coarctation aorta , renovascular stenosis , etc . ) Presence clinically significant ventricular supraventricular arrhythmia , second third degree atrioventricular block , sick sinus syndrome ALAT [ SGPT ] &gt; 2 time upper limit， ASAT [ SGOT ] &gt; 2 time upper limit Patients know renal disease Serum potassium &gt; normal upper limit Uncontroled BD（FBG＞10mmol/L PBG＞12.22mmol/L ) Patients treat tricyclic antidepressant Clinical hematological disease . Patients history irbesartan , hydrochlorothiazide sensitivity define irbesartan , hydrochlorothiazide discontinuation due medically significant adverse effect . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>